



American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: summary and recommendations

Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE

Larissa L. Fujii-Lau, MD,¹ Nirav C. Thosani, MD,² Mohammad Al-Haddad, MD, MSc, FASGE,³ Jared Acoba, MD,⁴ Curtis J. Wray, MD, MS, FACS,⁵ Rodrick Zvavanjanja, MD, Msc, FRCR(UK), FSIR, DABR(VIR/DR),⁶ Stuart K. Amateau, MD, PhD, FASGE,⁷ James L. Buxbaum, MD, MS, FASGE,⁸ Audrey H. Calderwood, MD, MS, FASGE,⁹ Jean M. Chalhoub, MD,¹⁰ Nayantara Coelho-Prabhu, MD, FASGE,¹¹ Madhav Desai, MD, MPH,¹² Sherif E. Elhanafi, MD,¹³ Douglas S. Fishman, MD, FAAP, FASGE,¹⁴ Nauzer Forbes, MD, MSc, FASGE,¹⁵ Laith H. Jamil, MD, FASGE,¹⁶ Terry L. Jue, MD, FASGE,¹⁷ Divyanshu R. Kohli, MD,¹⁸ Richard S. Kwon, MD, FASGE,¹⁹ Joanna K. Law, MD, FRCPC, FASGE,²⁰ Jeffrey K. Lee, MD, MPH,²¹ Jorge D. Machicado, MD, MPH,¹⁹ Neil B. Marya, MD,²² Swati Pawa, MD, FASGE,²³ Wenly Ruan, MD,¹⁴ Mandeep S. Sawhney, MD, MS, FASGE,²⁴ Sunil G. Sheth, MD, FASGE,²⁴ Andrew Storm, MD,¹¹ Nikhil R. Thiruvengadam, MD,²⁵ Bashar J. Qumseya, MD, MPH, FASGE²⁶
(ASGE Standards of Practice Committee Chair, 2020-2023)

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy provides an evidence-based approach for the diagnosis of malignancy in patients with biliary strictures of undetermined etiology. This document was developed using the Grading of Recommendations Assessment, Development and Evaluation framework and addresses the role of fluoroscopic-guided biopsy sampling, brush cytology, cholangioscopy, and EUS in the diagnosis of malignancy in patients with biliary strictures. In the endoscopic workup of these patients, we suggest the use of fluoroscopic-guided biopsy sampling in addition to brush cytology over brush cytology alone, especially for hilar strictures. We suggest the use of cholangioscopic and EUS-guided biopsy sampling especially for patients who undergo nondiagnostic sampling, cholangioscopic biopsy sampling for nondistal strictures and EUS-guided biopsy sampling distal strictures or those with suspected spread to surrounding lymph nodes and other structures. (Gastrointest Endosc 2023; ■:1-9.)

This guideline document was prepared by the Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy using the best available scientific evidence and considering a multitude of variables including but not limited to adverse events, patient values, and cost implications. The purpose of these guidelines is to provide the best practice recommendations that may help standardize patient care, improve patient outcomes, and reduce variability in practice. We recognize that clinical decision-making is complex. Guidelines, therefore, are not a substitute for a clinician's judgment. Such judgements may at times seem contradictory to our guidance because of many factors that are impossible to fully consider by guideline developers. Any clinical decisions should be based on the clinician's experience, local expertise, resource availability, and patient values and preferences. This document

is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating for, mandating, or discouraging any particular treatment. Our guidelines should not be used in support of medical complaints, legal proceedings, and/or litigation, as they were not designed for this purpose.

Cholangiocarcinoma is a rare malignancy with an approximate incidence of 8000 cases per year in the United States,¹ although it is increasing in frequency.^{2,3} The prognosis of cholangiocarcinoma is poor, with an overall 5-year survival rate of about 10%; however, diagnosis at an earlier stage results in a higher likelihood of survival.¹ Therefore, it is important to diagnose malignancy as soon as possible when patients present with biliary strictures.

Patients presenting with biliary strictures of undetermined etiology often pose a diagnostic challenge. It is

estimated that the risk of malignancy in patients with a biliary stricture without an obvious mass on cross-sectional imaging is approximately 55%.⁴ Benign etiologies of biliary strictures associated with diseases include primary sclerosing cholangitis, IgG subclass 4-related sclerosing cholangitis, fibrotic strictures, and chronic pancreatitis. The appearance of a benign biliary stricture on cross-sectional imaging often mimics the appearance of a malignant biliary stricture. Thus, tissue acquisition is required to distinguish malignant and benign biliary strictures.

Diagnostic modalities for biliary strictures are limited; however, endoscopic approaches are preferred over percutaneous sampling approaches, which require an external drain and risk needle-track seeding, or surgical approaches. Tissue acquisition in biliary strictures relies heavily on endoscopic techniques such as ERCP with brush cytology, intraductal biopsy sampling, cholangioscopy, or EUS with FNA or fine-needle biopsy sampling (FNB). However, these techniques have limitations, particularly low sensitivity for the diagnosis of malignancy and needle-track seeding in the setting of EUS-guided FNA of hilar strictures.⁵ The diagnosis of malignancy in biliary strictures often requires multiple procedures, resulting in increased cost and patient anxiety as well as delays in diagnosis and potential curative treatment. Therefore, the aim of this guideline is to provide evidence-based recommendations for the endoscopic approach to undetermined biliary strictures.

METHODS

This document was prepared by the Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) and was conceptualized and conducted according to the Grading of Recommendations Assessment, Development and Evaluation framework.⁶⁻⁸ Evidence was presented to a panel of experts representing various stakeholders, including a surgical oncologist, medical oncologist, and interventional radiologist. A patient advocate was also included. All panel members were required to disclose potential financial and intellectual conflicts of interest, which were addressed according to ASGE policies. In developing these recommendations, we took into consideration the certainty of the evidence, benefits, and harms of different management options, feasibility, patient values and preferences, resource utilization, cost-effectiveness, and health equity. The final wording of the recommendations, including direction and strength, were approved by all members of the panel and the ASGE governing board. Stronger recommendations are typically stated as “we recommend...,” whereas weaker recommendations are indicated by phrases such as “we suggest...”

These guidelines addressed the following 3 clinical questions using the Grading of Recommendations Assessment, Development and Evaluation format:

1. In patients with undetermined biliary strictures, should ERCP with fluoroscopic-guided biopsy sampling be performed versus ERCP with brush cytology to diagnose malignancy?
2. In patients with undetermined biliary strictures, should ERCP with cholangioscopic-guided biopsy sampling be performed versus ERCP without cholangioscopy to diagnose malignancy?
3. In patients with undetermined biliary strictures, should EUS with FNA/FNB be performed versus ERCP with any form of tissue acquisition to diagnose malignancy?

Indeterminate biliary strictures historically have been defined as a stricture in which prior ERCP had inconclusive cytology results. However, this guideline used the term *undetermined* biliary strictures rather than *indeterminate* biliary strictures because that term enabled the inclusion of studies of patients undergoing their first ERCP without a prior negative brush cytology. It is important to make this distinction to emphasize the importance of other forms of tissue acquisition that can be used in addition to brush cytology in the initial diagnostic workup of biliary strictures suspected to have underlying malignancy.

Relevant clinical outcomes were incremental yield, diagnostic test characteristics (sensitivity, specificity, positive predictive value, and negative predictive value), technical success, specimen adequacy, and adverse events. Technical success was defined as the percentage of cases where the endoscopist was able to perform the desired tissue sampling, whereas specimen adequacy was defined as a pathologic diagnosis with enough cellular components to make a determination of malignant or benign.

RESULTS AND SUMMARY OF RECOMMENDATIONS

Details of our literature searches, data analyses, pooled-effects estimates, evidence profiles, forest plots, and panel deliberations for each outcome can be found in the accompany article subtitled “Methodology and Review of Evidence.” A summary of our final recommendations is listed in [Table 1](#).

Question 1: In patients with biliary strictures of undetermined etiology, should ERCP with fluoroscopic-guided biopsy sampling be performed in addition to brush cytology versus ERCP with brush cytology alone to diagnose malignancy?

Recommendation 1. In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests the addition of fluoroscopic-guided biopsy sampling with brush cytology versus brush cytology alone to diagnose malignancy.

(Conditional recommendation/very low quality of evidence)

TABLE 1. Summary of recommendations

Question	Recommendation	Quality of evidence	General concepts
1	In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests the addition of fluoroscopic-guided biopsy sampling with brush cytology versus brush cytology alone to diagnose malignancy.	Conditional recommendation, very low quality of evidence	<ul style="list-style-type: none"> Review all cross-sectional imaging. Discuss patient in a multidisciplinary board or committee.
2	In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests the use of cholangioscopic-guided biopsy sampling in A, Nondistal biliary strictures where there is a high probability of adequate drainage of the critical liver segment or B, Previous nondiagnostic ERCP without cholangioscopy, and C, Centers with clinical expertise and easy access to the equipment. Otherwise, the ASGE suggests ERCP with or without cholangioscopy in the diagnosis of malignancy.	Conditional recommendation, very low quality of evidence	<ul style="list-style-type: none"> Discuss results with dedicated GI pathologist. Ensure careful alignment and advancement of forceps into the common bile duct under fluoroscopic guidance.
3	In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests EUS in addition to ERCP for the diagnosis of malignancy in the presence of A, Prior ERCP with nondiagnostic ERCP results, B, Distal biliary stricture, or C, Presence of lymphadenopathy or metastatic disease on cross-sectional imaging,	Conditional recommendation, very low quality of evidence	<ul style="list-style-type: none"> Upfront EUS should be considered in centers with the ability to do EUS and ERCP in the same session. If EUS is performed in the setting of hilar strictures, it is important for the endoscopist to avoid biopsy sampling of the biliary mass itself.

ASGE, American Society for Gastrointestinal Endoscopy.

Summary of evidence

A de novo systematic review and meta-analysis identified 21 observational studies (20 full text, 1 abstract) with 2726 patients that compared ERCP with fluoroscopic-guided biopsy sampling in combination with brush cytology versus brush cytology alone.⁹⁻²⁹ The incremental yield of intraductal biopsy sampling with brush cytology over brush cytology alone was 20% (95% confidence interval [CI], 9-31; $I^2 = 54.5\%$) in diagnosing malignancy.^{13,15,16,20,22,23,28} The miss rate of brush cytology alone was 58% (95% CI, 46-71; $I^2 = 79.5\%$) in diagnosing malignancy, whereas the miss rate of biopsy sampling alone was 41% (95% CI, 31-52; $I^2 = 80.3\%$).^{9,13,15,20,23,28,30} The sensitivity of brush cytology alone was .4 (95% CI, .37-.43; $I^2 = 69.5\%$).^{9,10,12-20,25-27,29,31} The sensitivity of fluoroscopic-guided biopsy sampling was significantly higher at .52 (95% CI, .49-.56; $I^2 = 79.4\%$; $P = .006$), as was the sensitivity of fluoroscopic-guided biopsy sampling in combination with brush cytology at .66 (95% CI, .63-.69; $I^2 = 48.4\%$; $P < .001$)^{9-13,15-20,22,24-28} compared with brush cytology alone. Subgroup analyses did not reveal a difference in the sensitivity of brushings versus biopsy sampling for proximal or distal strictures and biliary or pancreatic masses.

There was no difference in technical success of brush cytology and fluoroscopic-guided biopsy sampling in the reported studies (odds ratio, 3.27; 95% CI, .52-20.53; $I^2 = 65\%$).^{9,15,16,18,20,21,24,27} Nevertheless, the panel acknowledged that intraductal biopsy sampling is technically more difficult to obtain and requires more expertise because it is often typically performed without direct endoscopic visualization. Therefore, some studies may not have necessarily attempted intraductal biopsy sampling in all strictures. Based on our analysis, specimen adequacy was higher for brush cytology,^{9,10,15,16,18-21,24,26,28} but this was based on an intention-to-treat analysis and hence is likely a reflection of the technical difficulty and failures of fluoroscopic-guided biopsy sampling rather than the specimen quality itself. There was no difference in adverse events between brush cytology and intraductal biopsy sampling (odds ratio, .53; 95% CI, .14-2.05; $I^2 = 0\%$),^{15,16,19-21,26,29} although the overall number of events was low at 2 and 5 patients (out of >500 in each group) in the brush cytology and intraductal biopsy sampling groups, respectively. However, 2 severe adverse events of prolonged bleeding and perforation requiring surgical choledochotomy occurred in the fluoroscopic-guided biopsy group.

Our literature search on this topic revealed no significant difference in costs or health equity with intraductal biopsy sampling or brush cytology. A cost utility study showed that biopsy sampling was cost-effective based on a willingness-to-pay threshold of less than \$50,000.³²

Based on the increased incremental yield, lower miss rate, higher sensitivity, and overall low adverse event rate, the panel was in favor of adding fluoroscopic-guided biopsy sampling to cytology brushings in the workup of biliary strictures of undetermined origin. The panel expressed some concerns about the feasibility and safety of intraductal biopsy sampling because it is more technically challenging, is more time-consuming, and resulted in more severe adverse events than brush cytology alone. Therefore, the panel made a conditional recommendation acknowledging that biopsy sampling should be performed either at tertiary care centers or where there is endoscopic expertise.

Question 2: In patients with biliary strictures of undetermined etiology, should ERCP with cholangioscopic-guided biopsy sampling be performed versus ERCP without cholangioscopy to diagnose malignancy?

Recommendation 2. In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests the use of cholangioscopic-guided biopsy sampling in

- Nondistal biliary strictures where there is a high probability of adequate drainage of the critical liver segment or
- Previous nondiagnostic ERCP without cholangioscopy and
- Centers with clinical expertise and easy access to the equipment.

Otherwise, the ASGE suggest ERCP with or without cholangioscopy in the diagnosis of malignancy.

(Conditional recommendation/very low quality of evidence)

Summary of evidence

A de novo systematic review and meta-analysis identified 13 studies (1 randomized control trial, 12 observational studies)^{9,10,14,30,33-41} with 1529 patients who underwent ERCP with cholangioscopy and ERCP with other means of tissue acquisition, such as fluoroscopic-guided biopsy sampling, brush cytology, or both. The incremental yield of ERCP with cholangioscopy over ERCP without cholangioscopy was 27% (95% CI, 9-46; $I^2 = 56.8\%$) in 4 observational studies^{9,30,33,36} and 41% (95% CI, 11-72) in the only randomized controlled trial evaluating this outcome.³⁰ The sensitivity of ERCP with cholangioscopy was significantly higher than ERCP without cholangioscopy (.72 [95% CI, .66-.77; $I^2 = 71.8\%$] vs .61 [95% CI, .57-.66; $I^2 = 79.9\%$], respectively; $P = .001$).^{9,10,14,30,33-41} One study reported a higher sensitivity for distal strictures during ERCP with intraductal biopsy sampling (sensitivity, 76%) compared with ERCP with

cholangioscopic-guided biopsy sampling (sensitivity, 50%).³⁴ No difference in sensitivity was found between ERCP with and without cholangioscopy for proximal bile duct strictures in this study.

There was no difference in technical success,^{9,30,33} specimen adequacy (.96; 95% CI, .23-4; $I^2 = 0\%$),^{9,30,33,34} or adverse events (.58; 95% CI, .26-1.26; $I^2 = 0\%$)^{30,35,38} between ERCP with and without cholangioscopy. The most common adverse event for both groups was acute pancreatitis, with most cases being mild episodes. One study reported that additional time was needed to do the cholangioscopy portion of the ERCP, at 14 minutes (95% CI, 10-20).⁹

As expected, cholangioscopy has a higher cost. One study quoted an additional \$2637 when cholangioscopy was done during ERCP with stent placement.⁴² Furthermore, access to cholangioscopy is limited primarily to tertiary referral centers with experienced operators. However, the use of cholangioscopy has been shown to be cost-effective and decreases the overall number of procedures and costs required to diagnose malignancy.³² In patients with primary sclerosing cholangitis, cholangioscopy had an incremental quality-adjusted life-years gain of .22 at an additional cost of \$8562.44.³² This resulted in a base-case incremental cost-effectiveness ratio of \$39,277.25, which is below the willingness-to-pay threshold of less than \$50,000. In this study, cholangioscopy was more cost-effective than brush cytology, fluoroscopic-guided biopsy sampling, and fluorescence in situ hybridization analysis.

Based on the incremental yield of at least 27% higher sensitivity, no difference in adverse events, and overall cost-effectiveness, the panel was in favor of ERCP with cholangioscopy in the diagnostic approach for undetermined biliary strictures. However, with a lack of widespread availability, higher cost, and need for additional training on the technicalities of cholangioscopy, the panel emphasized the importance of cholangioscopy being performed at a tertiary center with expertise in this technique. Furthermore, because cholangioscopy is often difficult and less accurate in the very distal portion of the bile duct because of cholangioscope instability and difficulty passing the mini-forceps, cholangioscopy may not be the optimal approach for distal biliary strictures.

The panel emphasized the importance of adequate proximal biliary segment drainage after cholangioscopy. Because cholangioscopy requires the instillation of water or saline solution, there is a risk of introducing infection into the proximal biliary tree if it is not drained adequately.⁴³ Therefore, some experts on the panel expressed preference to not perform cholangioscopy during the initial ERCP but rather wait until the decompression of the proximal ducts is ensured, whereas others would consider cholangioscopy during the initial session as long as drainage of the proximal ducts appeared to be feasible.

Although this guideline focused on cholangioscopy-guided biopsy sampling, the panel wanted to also emphasize

the importance of interpreting the visualized images during cholangioscopy to help differentiate benign versus malignant strictures. Malignant strictures can appear nodular, papillary, or infiltrative.⁴⁴ Nodular masses have irregular mucosa with severe neovascularization that can obstruct the lumen, whereas papillary masses have numerous papillary projections and less neovascularization, and infiltrative masses cause luminal narrowing without a discrete mass but have more whitish mucosal discoloration and neovascularization. Understanding the distinguishing features of a malignant stricture can assist with targeting cholangioscopic-guided biopsy sampling to potentially increase the diagnostic yield of this technique.

Question 3: In patients with biliary strictures of undetermined etiology, should EUS with FNA or FNB be performed versus ERCP with any form of tissue acquisition to diagnose malignancy?

Recommendation 3. In patients with biliary strictures of undetermined etiology undergoing ERCP, the ASGE suggests EUS in addition to ERCP for the diagnosis of malignancy in the presence of

- Prior ERCP with nondiagnostic ERCP results,
- Distal biliary stricture, or
- Presence of lymphadenopathy or metastatic disease on cross-sectional imaging.

(Conditional recommendation/very low quality of evidence)

Summary of evidence

A meta-analysis by Chiang et al⁴⁴ on the incremental benefit of EUS over ERCP was identified. A systematic review of the topic did not find any additional studies. In this meta-analysis, the incremental benefit of EUS after nondiagnostic ERCP with brush cytology was found to be 15% (95% CI, 9-24; $I^2 = 0\%$). In 11 studies, the pooled sensitivity of ERCP alone with any method of tissue acquisition was no different from EUS alone (ERCP sensitivity .7 [95% CI, .66-.73; $I^2 = 86.6\%$] vs EUS sensitivity .74 [95% CI, .71-.77; $I^2 = 90\%$; $P = .31$).^{17,23,29,37,38,45-49} However, in 8 studies, the pooled sensitivity of combined EUS + ERCP was significantly higher than ERCP alone (ERCP + EUS sensitivity .88 [95% CI, .85-.91; $I^2 = 53.6\%$] vs ERCP alone sensitivity .61 [95% CI, .57-.64; $I^2 = 86.4\%$], respectively; $P < .001$).^{17,23,37,46-50} On subgroup analyses, EUS had a higher sensitivity than ERCP for distal strictures (.82 [95% CI, .76-.87] vs .62 [95% CI, .55-.69], respectively)^{17,45} and pancreatic masses (.82 [95% CI, .78-.86] vs .46 [95% CI, .4-.51], respectively; $P < .0001$).^{17,23,45,46,48,49}

There was no difference in technical success^{17,46-48,50} or specimen adequacy^{17,48,49} when comparing ERCP and EUS. EUS had a significantly lower adverse event rate (OR, 8.11; 95% CI, 2.95-22.29), with only 3 minor bleeding episodes occurring with EUS-guided FNA compared with 44 adverse

events with ERCP (1 severe pancreatitis, 27 mild pancreatitis, 10 cholangitis, and 6 mild bleeding).^{29,37,38,46,49,51} According to 1 study that used historical control subjects, EUS added an average of 23 minutes (95% CI, 14-32) to the procedure time.⁵⁰

There was a minor cost increase when EUS and ERCP were performed in the same session. Although 1 study reported the cost of EUS with FNA to be \$1076.25, the panel stressed that the cost is much lower when combined with ERCP than when performed alone.⁴² EUS was found to be cost-effective in patients with biliary strictures even without a discrete mass.⁵² The panel took into account that EUS is not as widely available throughout the country as compared with ERCP.

With the incremental benefit of EUS, lower adverse event rate, and cost-effectiveness, the panel was in favor of performing EUS in patients with biliary strictures of undetermined etiology. It was clear that EUS is beneficial in the setting of distal biliary strictures, and if a pancreatic mass, lymphadenopathy, or metastatic disease is noted within reach of the echoendoscope on cross-sectional imaging, then EUS should be performed. Some experts on the panel routinely performed EUS combined with ERCP on any biliary stricture, whereas others were less keen to perform EUS on proximal strictures because of the lower diagnostic yield and additional time involved. A risk of needle-tract seeding must be emphasized during EUS-guided FNA or FNB of hilar cholangiocarcinoma that may exclude patients from undergoing liver transplantation.⁵ Therefore, if an EUS is performed in the setting of proximal or hilar strictures, the endosonographer should *not* perform FNA or FNB of the biliary mass itself.

OTHER CONSIDERATIONS

The panel considered other endoscopic techniques such as intraductal US (IDUS) and confocal laser endomicroscopy, which have been studied in patients with biliary strictures. IDUS findings that are suggestive of malignancy are an intraluminal mass with an irregular margin, wall thickness >9 mm, heterogeneous lesion with an uneven mucosal surface, eccentric wall thickening, destruction of the wall layers, and masses that invade the surrounding tissue.^{53,54} IDUS has been shown to increase the sensitivity of diagnosing malignant strictures compared with ERCP alone.⁵⁵⁻⁵⁷ Our previous guidelines consider IDUS is a promising technique in the evaluation of indeterminate biliary strictures.⁵⁸ Because it is more widely available now, IDUS could potentially be considered to help localize the malignant-appearing region for targeted biopsy sampling. One study showed the diagnostic accuracy of IDUS-guided transpapillary biopsy sampling was significantly higher than transpapillary biopsy sampling alone (90.8% vs 76.9% respectively; $P = .028$).⁵⁹ However, the utility of this techniques needs to be further studied before a

recommendation can be made on its widespread adoption into clinical practice.

Similarly, confocal laser endomicroscopy uses thin confocal laser probes inserted through the working channel of the duodenoscope (probe-based confocal laser endomicroscopy). A group of endoscopists formed the Miami classification system based on consensus to help differentiate benign versus malignant biliary stricture.⁶⁰ Malignant biliary strictures included thick dark bands of the collagen fibrils and thickened white bands within the vessels. A limitation of the Miami classification is the low interobserver agreement. Subsequently, the Paris classification further defined the criteria for benign inflammatory strictures including vascular congestion, dark granular patterns with scales, increased interglandular space, and thickened reticular structures.⁶¹ A meta-analysis had a pooled sensitivity of 90% (95% CI, 86-94; $I^2 = 1.6\%$) and specificity of 72% (95% CI, 65-79; $I^2 = 0\%$).⁶² One systematic review mentioned that its best application may be a high negative predictive value for malignancy of 94%.⁶³ Based on this, the panel noted that confocal laser endomicroscopy is difficult to master and also expensive. Therefore, its widespread adoption is likely limited in the near future.

FUTURE DIRECTIONS

Our systematic literature review highlighted several areas in need of additional higher quality data to inform the role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology. Future studies should address the following:

1. Randomized control trials to address the above clinical questions to improve our knowledge on the topic
2. Focus on patients with primary sclerosing cholangitis because the diagnostic algorithm may change in this patient population where fluorescence in situ hybridization analysis plays a higher role
3. Role on technologic developments such as mini overtubes to facilitate intraductal biopsy sampling, improvements on cholangioscopy platforms and tissue sampling devices, and novel imaging modalities such as confocal laser microscopy to improve the diagnosis of biliary malignancies
4. Role of adjunctive pathologic analyses such as next-generation sequencing, flow cytometry, fluorescence in situ hybridization analysis, and digital image analysis in the diagnostic algorithm
5. Diagnostic yield of performing cholangioscopy and/or EUS on consecutive patients who present with biliary strictures (instead of limited to those in whom cholangioscopy is technically successful)
6. Interval of time before next ERCP(s) when nondiagnostic
7. Utility of artificial intelligence-guided visual interpretation and artificial intelligence-guided sampling during cholangioscopy and EUS for indeterminate biliary strictures

SUMMARY AND CONCLUSIONS

These ASGE guidelines used the best available evidence to make recommendations for the role of endoscopy in the diagnosis of malignancy in patients with biliary strictures of undetermined etiology. If the endoscopic expertise is available, it is suggested that ERCP with fluoroscopic-guided biopsy sampling and brush cytology should be performed for any location of the biliary stricture, whereas cholangioscopy and EUS should also be considered, particularly in nondistal and distal biliary strictures, respectively.

GUIDELINE UPDATE

ASGE guidelines are reviewed for updates approximately every 5 years or in the event that new data may influence a recommendation. Updates follow the same ASGE guideline development process.

DISCLOSURE

The following authors disclosed financial relationships: L. L. Fujii-Lau: Food and beverage compensation from Pfizer Inc and AbbVie Inc. N. C. Thosani: Consultant for Pentax of America, Inc, Boston Scientific Corporation, and Ambu Inc; travel compensation and food and beverage compensation from Pentax of America, Inc, Boston Scientific Corporation, and AbbVie Inc; speaker for AbbVie Inc. M. Al-Haddad: Research support from Creatics, LLC and Amplified Sciences. S. K. Amateau: Consultant for Boston Scientific Corporation, Merit Medical, Olympus Corporation of the Americas, MT Endoscopy, US Endoscopy, Heraeus Medical Components, LLC, and Cook Medical LLC; travel compensation Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation, Olympus Corporation of the Americas, and Cook Medical LLC; advisory board for Merit Medical. J. L. Buxbaum: Consultant for Boston Scientific Corporation, Cook Medical LLC, and Olympus America Inc; travel compensation and food and beverage compensation from Boston Scientific Corporation. A. H. Calderwood: Advisory board for Dark Canyon Laboratories LLC. J. M. Chalhoub: Travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Boston Scientific Corporation. N. Coelho-Prabhu: Consultant for Boston Scientific Corporation and Alexion Pharma; research support from Cook Endoscopy and Fujifilm; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. S. E. Elhanafi: Food and beverage compensation from Medtronic, Inc, Nestle HealthCare Nutrition Inc, Ambu Inc, Salix Pharmaceuticals, Takeda Pharmaceuticals USA, Inc, and Merit Medical Systems Inc. D. S. Fishman: Royalties from UpToDate. N. Forbes: Consultant for Boston Scientific

Corporation, Pentax of America, Inc, AstraZeneca, and Pendopharm Inc; speaker for Pentax of America, Inc and Boston Scientific Corporation; research support from Pentax of America, Inc. T. L. Jue: Travel compensation from Creo Medical. D. R. Kohli: Research support from Olympus Corporation of the Americas. J. D. Machado: Consultant for Mauna Kea Technologies, Inc; food and beverage compensation from Mauna Kea Technologies, Inc and Boston Scientific Corporation. N. B. Marya: Consultant for Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US Inc. M. S. Sawhney: Stockholder with Allurion Technology, Inc; research support from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Olympus America Inc. S. G. Sheth: Consultant for Janssen Research & Development, LLC; food and beverage compensation from Medtronic, Inc. A. Storm: Consultant for Apollo Endosurgery US Inc, Boston Scientific Corporation, Intuitive Surgical Inc, Olympus America Inc, and Medtronic; research support from Apollo Endosurgery US Inc, Boston Scientific Corporation, Endogenex, and Enterasense; travel compensation from Apollo Endosurgery US Inc and Intuitive Surgical Inc; food and beverage compensation from Apollo Endosurgery US Inc, Boston Scientific Corporation, Intuitive Surgical Inc, Olympus America Inc, and Micro-Tech Endoscopy USA, Inc; data safety board for GI Dynamics and Erbe. N. R. Thiruvengadam: Research support from Boston Scientific Corporation. B. J. Qumseya: Consultant for Medtronic, Inc and Assertio Management, LLC; food and beverage compensation from Medtronic, Inc, Fujifilm Healthcare Americas Corporation, and Boston Scientific Corporation; speaker for Castle Biosciences. All other authors disclosed no financial relationships.

ACKNOWLEDGMENTS

We are grateful to Toni Pham from the Cholangiocarcinoma Foundation for her input as a patient advocate on this guideline panel and to Kellee Kaulback (librarian) and Robyn Rosasco (librarian) for assistance with searching for articles. We also thank Dr Tiffany Chua and Dr Ramzi Mulki on behalf of the *Gastrointestinal Endoscopy* Editorial Board and Dr Bret Petersen for their review of the guidelines. This guideline was funded exclusively by the American Society for Gastrointestinal Endoscopy; no outside funding was received to support the development of this guideline.

REFERENCES

1. American Cancer Society. Key statistics for bile duct cancer. Available at: <https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html>. Accessed March 11, 2022.
2. Castro FA, Koshiol J, Hsing AW, et al. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. *Int J Cancer* 2013;133:1664-71.
3. Banales JM, Marin JGG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol* 2020;17:557-88.
4. Burnett AS, Calvert TJ, Chokshi RJ. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature. *J Surg Res* 2013;184:304-11.
5. Heimbach JK, Sanchez W, Rosen CB, et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. *HPB* 2011;13:356-60.
6. Jackson R, Feder G. Guidelines for clinical guidelines. *BMJ* 1998;317:427-8.
7. Wani S, Sultan S, Qumseya B, et al. The ASGE's vision for developing clinical practice guidelines: the path forward. *Gastrointest Endosc* 2018;87:932-3.
8. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
9. Draganov PV, Chauhan S, Wagh MS, et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. *Gastrointest Endosc* 2012;75:347-53.
10. Han S, Tatman P, Mehrotra S, et al. Combination of ERCP-based modalities increases diagnostic yield for biliary strictures. *Dig Dis Sci* 2021;66:1276-84.
11. Hormati A, Jafari S, Jabbari A, et al. Comparison between brush cytology and forceps biopsy under fluoroscopic guidance for the diagnosis of proximal cholangiocarcinoma. *Middle East J Dig Dis* 2020;12:246-51.
12. Howell DA, Parsons WG, Jones MA, et al. Complete tissue sampling of biliary strictures at ERCP using a new device. *Gastrointest Endosc* 1996;43:498-502.
13. Jailwala J, Fogel EL, Sherman S, et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. *Gastrointest Endosc* 2000;51:383-90.
14. Kaura K, Sawas T, Bazerbachi F, et al. Cholangioscopy biopsies improve detection of cholangiocarcinoma when combined with cytology and FISH, but not in patients with PSC. *Dig Dis Sci* 2020;65:1471-8.
15. Kitajima Y, Ohara H, Nakazawa T, et al. Usefulness of transpapillary bile duct brushing cytology and forceps biopsy for improved diagnosis in patients with biliary strictures. *J Gastroenterol Hepatol* 2007;22:1615-20.
16. Kulaksiz H, Strnad P, Römpf A, et al. A novel method of forceps biopsy improves the diagnosis of proximal biliary malignancies. *Dig Dis Sci* 2011;56:596-601.
17. Moura DTH, de Moura EGH, Matuguma SE, et al. EUS-FNA versus ERCP for tissue diagnosis of suspect malignant biliary strictures: a prospective comparative study. *Endosc Int Open* 2018;6:E769-77.
18. Naitoh I, Nakazawa T, Kato A, et al. Predictive factors for positive diagnosis of malignant biliary strictures by transpapillary brush cytology and forceps biopsy. *J Dig Dis* 2016;17:44-51.
19. Ponchon T, Gagnon P, Berger F, et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. *Gastrointest Endosc* 1995;42:565-72.
20. Pugliese V, Antonelli G, Vincenti M, et al. Endoductal tissue sampling of biliary strictures through endoscopic retrograde cholangiopancreatography (ERCP). *Tumori* 1997;83:698-702.
21. Pugliese V, Barone D, Saccomanno S, et al. Tissue sampling from the common bile duct through endoscopic retrograde cholangiopancreatography, endoscopic papillo(sphincter)otomy and drainage in juxta-papillary malignancies. *Surg Endosc* 1987;1:83-7.
22. Ren YC, Huang CL, Chen SM, et al. Dilation catheter-guided mini-forceps biopsy improves the diagnostic accuracy of malignant biliary strictures. *Endoscopy* 2018;50:809-12.
23. Rösch T, Hofrichter K, Frimberger E, et al. ERCP or EUS for tissue diagnosis of biliary strictures? A prospective comparative study. *Gastrointest Endosc* 2004;60:390-6.

24. Sakuma Y, Kodama Y, Sogabe Y, et al. Diagnostic performance of a new endoscopic scraper for malignant biliary strictures: a multicenter prospective study. *Gastrointest Endosc* 2017;85:371-9.
25. Salomao M, Gonda TA, Margolske E, et al. Strategies for improving diagnostic accuracy of biliary strictures. *Cancer Cytopathol* 2015;123:244-52.
26. Schoefl R, Haefner M, Wrba F, et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. *Scand J Gastroenterol* 1997;32:363-8.
27. Sugiyama M, Atomi Y, Wada N, et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. *Am J Gastroenterol* 1996;91:465-7.
28. Weber A, von Weyhern C, Fend F, et al. Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma. *World J Gastroenterol* 2008;14:1097-101.
29. Yang X, Guo JF, Sun LQ, et al. Assessment of different modalities for repeated tissue acquisition in diagnosing malignant biliary strictures: a two-center retrospective study. *J Dig Dis* 2021;22:102-7.
30. Gerges C, Beyna T, Tang RSY, et al. Digital single-operator peroral cholangioscopy-guided biopsy sampling versus ERCP-guided brushing for indeterminate biliary strictures: a prospective, randomized, multicenter trial (with video). *Gastrointest Endosc* 2020;91:1105-13.
31. Reis DNF, Freitas C, Marques A, et al. Biopsies in combination with brush cytology can improve the characterization of malignant biliary strictures during ERCP. *United Eur Gastroenterol J* 2018;6:A609.
32. Njei B, McCarty TR, Varadarajulu S, et al. Cost utility of ERCP-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Gastrointest Endosc* 2017;85:773-81.
33. Fukuda Y, Tsuyuguchi T, Sakai Y, et al. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. *Gastrointest Endosc* 2005;62:374-82.
34. Hartman DJ, Slivka A, Giusto DA, et al. Tissue yield and diagnostic efficacy of fluoroscopic and cholangioscopic techniques to assess indeterminate biliary strictures. *Clin Gastroenterol Hepatol* 2012;10:1042-6.
35. Kato M, Onoyama T, Takeda Y, et al. Peroral cholangioscopy-guided forceps biopsy and endoscopic scraper for the diagnosis of indeterminate extrahepatic biliary stricture. *J Clin Med* 2019;8:873.
36. Kokoy-Mondragon CB, Amin S, Desai AP, et al. Comparison of accuracy of simultaneous cholangioscopic biopsies and fluorescence in-situ hybridization in biliary strictures. *Gastroenterology* 2017;152:S297-8.
37. Lee YN, Moon JH, Choi HJ, et al. Tissue acquisition for diagnosis of biliary strictures using peroral cholangioscopy or endoscopic ultrasound-guided fine-needle aspiration. *Endoscopy* 2019;51:50-9.
38. Onoyama T, Matsumoto K, Takeda Y, et al. Endoscopic ultrasonography-guided fine needle aspiration for extrahepatic cholangiocarcinoma: a safe tissue sampling modality. *J Clin Med* 2019;8:417.
39. Tischendorf JJ, Krüger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. *Endoscopy* 2006;38:665-9.
40. Walter D, Peveling-Oberhag J, Schulze F, et al. Intraductal biopsies in indeterminate biliary stricture: evaluation of histopathological criteria in fluoroscopy vs. cholangioscopy guided technique. *Dig Liver Dis* 2016;48:765-70.
41. Yan S, Tejaswi S. Clinical impact of digital cholangioscopy in management of indeterminate biliary strictures and complex biliary stones: a single-center study. *Ther Adv Gastrointest Endosc* 2019;12:2631774519853160.
42. Loras C, Mayor V, Fernández-Bañares F, et al. Study of the standard direct costs of various techniques of advanced endoscopy. Comparison with surgical alternatives. *Dig Liver Dis* 2018;50:689-97.
43. Othman MO, Guerrero R, Elhanafi S, et al. A prospective study of the risk of bacteremia in directed cholangioscopic examination of the common bile duct. *Gastrointest Endosc* 2016;83:151-7.
44. Chiang A, Theriault M, Salim M, et al. The incremental benefit of EUS for the identification of malignancy in indeterminate extrahepatic biliary strictures: a systematic review and meta-analysis. *Endosc Ultrasound* 2019;8:310-7.
45. Heinzow HS, Kammerer S, Rammes C, et al. Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. *World J Gastroenterol* 2014;20:10495-503.
46. Jo JH, Cho CM, Jun JH, et al. Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: a multicenter experience. *J Gastroenterol Hepatol* 2019;34:799-805.
47. Khan AH, Austin GL, Fukami N, et al. Cholangiopancreatography and endoscopic ultrasound for indeterminate pancreaticobiliary pathology. *Dig Dis Sci* 2013;58:1110-5.
48. Weillert F, Bhat YM, Binmoeller KF, et al. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. *Gastrointest Endosc* 2014;80:97-104.
49. Yeo SJ, Cho CM, Jung MK, et al. Comparison of the diagnostic performances of same-session endoscopic ultrasound- and endoscopic retrograde cholangiopancreatography-guided tissue sampling for suspected biliary strictures at different primary tumor sites. *Korean J Gastroenterol* 2019;73:213-8.
50. Oppong K, Raine D, Nayar M, et al. EUS-FNA versus biliary brushings and assessment of simultaneous performance in jaundiced patients with suspected malignant obstruction. *J Pancreat* 2010;11:560-7.
51. Hijioka S, Hara K, Mizuno N, et al. Diagnostic yield of endoscopic retrograde cholangiography and of EUS-guided fine needle aspiration sampling in gallbladder carcinomas. *J Hepatobiliary Pancreat Sci* 2012;19:650-5.
52. Oliver JB, Burnett AS, Ahlawat S, et al. Cost-effectiveness of the evaluation of a suspicious biliary stricture. *J Surg Res* 2015;195:52-60.
53. Krishna NB, Saripalli S, Safdar R, et al. Intraductal US in evaluation of biliary strictures without a mass lesion on CT scan or magnetic resonance imaging: significance of focal wall thickening and extrinsic compression at the stricture site. *Gastrointest Endosc* 2007;66:90-6.
54. Wang YS, Chuang CH, Wu JH, et al. Proposal of a diagnostic algorithm for intraductal ultrasonography to distinguish between benign and malignant biliary strictures. *Kaohsiung J Med Sci* 2017;33:351-8.
55. Farrell RJ, Agarwal B, Brandwein SL, et al. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. *Gastrointest Endosc* 2002;56:681-7.
56. Stavropoulos S, Larghi A, Verna E, et al. Intraductal ultrasound for the evaluation of patients with biliary strictures and no abdominal mass on computed tomography. *Endoscopy* 2005;37:715-21.
57. Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. *Gastrointest Endosc* 2002;56:372-9.
58. Tringali A, Lemmers A, Meves V, et al. Intraductal biliopancreatic imaging: European Society of Gastrointestinal Endoscopy (ESGE) technology review. *Endoscopy* 2015;47:739-53.
59. Kim HS, Moon JH, Lee YN, et al. Prospective comparison of intraductal ultrasonography-guided transpapillary biopsy and conventional biopsy on fluoroscopy in suspected malignant biliary strictures. *Gut Liver* 2018;12:463-70.
60. Wallace M, Lauwers GY, Chen Y, et al. Miami classification for probe-based confocal laser endomicroscopy. *Endoscopy* 2011;43:882-91.
61. Caillol F, Filoche B, Gaidhane M, et al. Refined probe-based confocal laser endomicroscopy classification for biliary strictures: the Paris Classification. *Dig Dis Sci* 2013;58:1784-9.
62. Fugazza A, Gaiani F, Carra MC, et al. Confocal laser endomicroscopy in gastrointestinal and pancreaticobiliary diseases: a systematic review and meta-analysis. *Biomed Res Int* 2016;2016:4638683.

63. Kim DH, Krishna SG, Coronel E, et al. Confocal laser endomicroscopy in the diagnosis of biliary and pancreatic disorders: a systematic analysis. *Clin Endosc* 2022;55:197-207.

Abbreviations: ASGE, American Society for Gastrointestinal Endoscopy; CI, confidence interval; FNB, fine-needle biopsy sampling; IDUS, intraductal ultrasound.

Copyright © 2023 by the American Society for Gastrointestinal Endoscopy 0016-5107/\$36.00

<https://doi.org/10.1016/j.gie.2023.06.005>

Received June 6, 2023. Accepted June 7, 2023.

Current affiliations: Department of Gastroenterology, University of Hawaii, Honolulu, Hawaii, USA (1), Center for Interventional Gastroenterology (2), Department of Surgery (5), Department of Diagnostic and Interventional Imaging (6), UTHealth, McGovern Medical School, Houston, Texas, USA; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA (3), Department of Hematology and Medical Oncology, University of Hawaii Cancer Center, Honolulu, Hawaii, USA (4), Division of Gastroenterology Hepatology and Nutrition, University of Minnesota Medical Center, Minneapolis, Minnesota, USA (7), Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA (8), Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire, USA (9), Department of Gastroenterology and Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York, USA (10), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Min-

nesota, USA (11), Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota Medical Center, Minneapolis, Minnesota, USA (12), Division of Gastroenterology, Texas Tech University Health Sciences Center, El Paso, Texas, USA (13), Division of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA (14), Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (15), Section of Gastroenterology and Hepatology, Beaumont Health, Royal Oak, and Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA (16), Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA (17), Pancreas and Liver Clinic, Providence Sacred Heart Medical Center, Spokane, Washington, USA (18), Division of Gastroenterology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA (19), Department of Gastroenterology and Hepatology, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, USA (20), Department of Gastroenterology, Kaiser Permanente San Francisco Medical Center, San Francisco, California, USA (21), Division of Gastroenterology and Hepatology, UMass Chan Medical School, Worcester, Massachusetts, USA (22), Department of Gastroenterology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA (23), Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA (24), Division of Gastroenterology and Hepatology, Loma Linda University, Loma Linda, California, USA (25), Department of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida, USA (26).

Reprint requests: Bashar J. Qumseya, MD, MPH, FASGE, Department of Gastroenterology, Hepatology and Nutrition, University of Florida, PO Box 100214, 1329 SW 16th St, Ste 5251, Gainesville, FL 32610-0214.